PMID- 27787270
OWN - NLM
STAT- MEDLINE
DCOM- 20170303
LR  - 20170817
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 42 Suppl 1
DP  - 2016 Nov
TI  - Prevention and Management of Injection-Related Adverse Effects in Facial 
      Aesthetics: Considerations for ATX-101 (Deoxycholic Acid Injection) Treatment.
PG  - S300-S304
AB  - ATX-101 (deoxycholic acid injection; Kythera Biopharmaceuticals, Inc. [an 
      affiliate of Allergan plc, Dublin, Ireland]) was approved in 2015 in the United 
      States (Kybella) and Canada (Belkyra) for submental fat reduction. As expected, 
      injection-site reactions such as pain, swelling, and bruising, which were mostly 
      mild or moderate and transient, were common adverse events (AEs) reported in 
      clinical trials. An exploratory Phase 3b study investigating interventions for 
      management of injection-site AEs associated with ATX-101 treatment was recently 
      completed. Based on its results, literature review, and our clinical experiences, 
      we have put forward considerations for management of AEs associated with ATX-101 
      treatment in clinical practice. Pretreatment with oral ibuprofen and/or 
      acetaminophen an hour before treatment and preinjection with 
      epinephrine-containing buffered lidocaine 15 minutes before treatment can help 
      with management of pain and bruising. Cold application to the treated area before 
      and immediately after the procedure may help to reduce pain (if local anesthetic 
      preinjection is not performed) and swelling. Discontinuing 
      medications/supplements that result in increased anticoagulant or antiplatelet 
      activity 7 to 10 days before ATX-101 treatment, when possible, can reduce the 
      risk of bruising. In summary, injection-site AEs associated with ATX-101 
      treatment can be effectively managed with commonly used interventions.
FAU - Fagien, Steven
AU  - Fagien S
AD  - *Private Practice, Boca Raton, Florida; daggerEvidence Scientific Solutions, 
      Philadelphia, Pennsylvania; double daggerDepartment of Dermatology, University of California 
      Los Angeles and Private Practice (Skin Care and Laser Physicians of Beverly 
      Hills), Los Angeles, California.
FAU - McChesney, Patricia
AU  - McChesney P
FAU - Subramanian, Meenakshi
AU  - Subramanian M
FAU - Jones, Derek H
AU  - Jones DH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (ATX-101 compound)
RN  - 0 (Dermatologic Agents)
RN  - 005990WHZZ (Deoxycholic Acid)
SB  - IM
MH  - Clinical Trials as Topic
MH  - Contusions/etiology/prevention & control/therapy
MH  - Cosmetic Techniques/*adverse effects
MH  - Deoxycholic Acid/administration & dosage/*adverse effects
MH  - Dermatologic Agents/administration & dosage/*adverse effects
MH  - Edema/etiology/prevention & control/therapy
MH  - Humans
MH  - Injections, Subcutaneous/*adverse effects
MH  - Pain, Postoperative/etiology/prevention & control/therapy
MH  - Postoperative Complications/etiology/prevention & control/therapy
MH  - Subcutaneous Fat/*drug effects
EDAT- 2016/10/28 06:00
MHDA- 2017/03/04 06:00
CRDT- 2016/10/28 06:00
PHST- 2016/10/28 06:00 [pubmed]
PHST- 2017/03/04 06:00 [medline]
PHST- 2016/10/28 06:00 [entrez]
AID - 00042728-201611001-00008 [pii]
AID - 10.1097/DSS.0000000000000898 [doi]
PST - ppublish
SO  - Dermatol Surg. 2016 Nov;42 Suppl 1:S300-S304. doi: 10.1097/DSS.0000000000000898.